The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects

Summary

The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.

Timeline

Start

2022-05-12

Primary completion

2022-05-26

Completion

2022-06-02

Publications

• Chen KG, Zhang YH, Ye PP, Gao XH, Song LL, Zhou HY, Li Q, Zhao FR, Shi JY, Yang XM, Shen K, Feng S, Zhao W. Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study. Front Pharmacol. 2023 Dec 22;14:1294810. doi: 10.3389/fphar.2023.1294810. eCollection 2023.

Drugs

Indications